A key development to watch in 2025: Eli Lilly (LLY) achieving a trillion-dollar market cap ... Under their brand names Wegovy (for obesity) and Ozempic (for Type 2 Diabetes), and Zepbound / Mounjaro, ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

Ozempic (generic name semaglutide) is a medication originally designed for managing ... Mounjaro (generic name Tirzepatide), ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...